# Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025

> **NCT02004392** · PHASE3 · TERMINATED · sponsor: **FORUM Pharmaceuticals Inc** · enrollment: 348 (actual)

## Conditions studied

- Alzheimer's Disease
- Dementia

## Interventions

- **DRUG:** EVP-6124

## Key facts

- **NCT ID:** NCT02004392
- **Lead sponsor:** FORUM Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 348 (ACTUAL)
- **Why stopped:** Study has been suspended due to clinical hold.
- **Last updated:** 2016-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02004392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02004392, "Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02004392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*